Theregen, Inc. is a regenerative medicine company developing Anginera™, an epicardial patch, for the treatment of heart disease. Anginera is a cell-based, three-dimensional human tissue patch that induces formation of mature blood vessels in the human myocardium. Theregen owns the exclusive worldwide rights to cardiovascular applications of Anginera, including all related technology and a supply agreement with Advanced BioHealing for manufacturing tissue for clinical trials.
In 2009, Theregen completed two Phase I clinical trials: a safety study in patients with reversible myocardial ischemia undergoing Coronary Artery Bypass Graft (CABG) surgery, and a study in patients who received a Left Ventricular Assist Device (LVAD) as a bridge to heart transplantation. Valuable histological data have been obtained from these studies. Theregen has demonstrated for the first time in humans that Anginera induces growth of mature blood vessels in underperfused cardiac tissue, which improves perfusion, and stimulates tissue repair. Next stage safety and efficacy studies will focus on the treatment of refractory angina due to ischemia that is not amenable to current therapies. Sanderling Ventures serves as Theregen's key investor and development advisor.